Will Molnupiravir be the First Oral Treatment for High-Risk Non-Hospitalized Patients with Mild-Moderate COVID-19?

Main Article Content

Sohail Rao
Manish Singh https://orcid.org/0000-0003-4146-3282

Keywords

COVID-19, SARS-CoV-2, FDA, Molnupiravir, Merck

Abstract 203 | PDF Downloads 266

References

1. COVID-19 dashboard. John Hopkins University of Medicine. 2021. https://coronavirus.jhu.edu/map.html (Accessed October 02, 2021; 21:48 p.m. CST)
2. FDA approves first COVID-19 vaccine. 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine
3. Available COVID-19 treatment option. 2021. https://combatcovid.hhs.gov/i-have-covid-19-now/available-covid-19-treatment-options
4. Nazario-Toole AE, Xia H, Gibbons TF. Whole-genome Sequencing of SARS-CoV-2: Using Phylogeny and Structural Modeling to Contextualize Local Viral Evolution [published online ahead of print, 2021 Feb 20]. Mil Med. 2021; usab031. doi:10.1093/milmed/usab031
5. Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Loftis AJ, Alabanza P, Lipansky F, Painter WP. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv [Preprint]. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639. PMID: 34159342; PMCID: PMC8219109.
6. Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study. Oct 01, 2021. https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
7. Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, Plesker R, Barrena AH, Reddy PG, Mitchell DG, Shean RC, Bluemling GR, Kolykhalov AA, Greninger AL, Natchus MG, Painter GR, Plemper RK. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515): eaax5866. doi: 10.1126/scitranslmed. aax5866. PMID: 31645453; PMCID: PMC6848974

Most read articles by the same author(s)

1 2 > >>